STAT April 30, 2024
Eli Lilly raised its full-year guidance on Tuesday while it reported strong first-quarter sales of Zepbound, even as the pharmaceutical company struggles to make enough of the obesity drug to meet the enormous demand.
Lilly increased its adjusted earnings guidance for 2024 to a range of $13.50 to $14.00 per share, up from a prior forecast of $12.20...